<DOC>
	<DOC>NCT00621010</DOC>
	<brief_summary>This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers</brief_summary>
	<brief_title>Safety Study of CTS21166 to Treat Alzheimer Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy adult male &gt; age 21; nonsmoker (minimum 6 months); History or evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, psychiatric, oncologic, or allergic (including anaphylactic drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease History or evidence of intravenous illicit drug use, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; Participation in another clinical trial within 30 days prior to dosing</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>